comparemela.com

Latest Breaking News On - Sensorion - Page 1 : comparemela.com

Sensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europe

MONTPELLIER, France, July 19, 2023 Sensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europe

United kingdomFrance generalCruz tapiaStuart isabelle abdouNawal ouzrenInstitut pasteurPierre louis germainEu community registerCommunications europe franceConsilium strategic communicationsEuropean medicines agencyRegulatory agencyDrug administrationInternational media relationsRegulatory newsClinical trial application

Sensorion Will Present Two Posters At The American Society Of Cell And Gene Therapy (ASGCT) 26th Annual Meeting

Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, is pleased to announce its participation in the

United statesLos angelesDavid lawrenceInstitut pasteurMatthew cole jessica hodgsonHead of preclinical developmentVector development platform for inner ear disordersPreclinical developmentCommunications europe franceInternational media relationsStrategic communicationsRegulatory newsChief medical officerAnnual meetingInner earWednesday may

Sensorion : Terms of availability of the preparatory documents for the GM

Press release Sensorion provides preliminary documents for the Combined shareholders General Meeting of May 24, 2023 . | May 3, 2023

France generalInstitut pasteurSquare louvoisGeneral meetingCombined general meetingFrench commercial codeAnnual general meetingCombined shareholder general meetingSensorion stock exchangePress releaseAy alsen fr0012596468

Sensorion Provides Preliminary Documents for the Combined Shareholders General Meeting of May 24, 2023

Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces that the Company's shareholders

France generalDavid lawrenceSquare louvoisInstitut pasteurCommunications europe franceConsilium strategic communicationsInternational media relationsRegulatory newsCombined general meetingFrench commercial codeGeneral meetingAnnual general meetingCombined shareholder general meetingCisplatin induced ototoxicityCochlear limitedSudden sensorineural hearing loss

Sensorion Announces the Publication of Its 2022 Annual Financial Report

30.03.2023 - Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces that its Annual Financial Report for the year ending December 31, 2022, is available .

Lang schwarzProfesseur joseph blayacInstitut pasteurCompany headquartersManagement reportAnnual accountsFinancial statementsAnnual financial reportFinancial informationCochlear limitedSudden sensorineuralHearing lossSensorion stock

vimarsana © 2020. All Rights Reserved.